STSA News and Press, Satsuma Pharmaceuticals Inc. From 07/07/20

SOUTH SAN FRANCISCO, Calif., July 07, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that it has appointed biopharmaceutical industry veteran Thomas M. Soloway to its Board of Directors effective July 2, 202...

Meeting Launch date is Saturday, June 13 th 2020 at 9:00am (PT) Safety of Dihydroergotamine for the Acute Treatment of Migraine: Reality vs Perception The Efficacy of Dihydroergotamine versus Emerging Acute Migraine Medications SOUTH SAN FRANCISCO, Calif., June 11, 2020 (GLO...

SOUTH SAN FRANCISCO, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today reported completion of enrollment and randomization in its EMERGE pivotal Phase 3 efficacy trial of STS101 (dihydroergotamine (DHE) ...

SOUTH SAN FRANCISCO, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins, President and Chief Executive Officer, is scheduled to present at the Jefferies Virtual Healthca...

Investment Thesis Fueled by a string of catalysts, the shares of Axsome Therapeutics, Inc. ( AXSM ) rose exponentially last year. After achieving the major milestones last year, the stock has declined so far as its net losses keep piling up amid the growing R&D expenditure. However, th...

            Pharmacokinetic comparison of STS101, an intranasal dry powder formulation of dihydroergotamine, with other intranasal, injectable and oral inhaled DHE formulations  Water-insoluble Mucoadhesive Formulation Enables Consistent and Rapi...

Satsuma Pharmaceuticals (NASDAQ: STSA ): Q1 GAAP EPS of -$0.68 misses by $0.01 . More news on: Satsuma Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

STS101 EMERGE™ Phase 3 efficacy trial remains on track with announcement of topline data  expected in second half of 2020 Company well-capitalized with cash, cash equivalents, and marketable securities of $104.1 million at the end of Q1 2020, providing runway through plann...

SOUTH SAN FRANCISCO, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, announced today that it will host a Key Opinion Leader (KOL) event discussing STS101 and the acute treatment of migraine on Tuesday, May ...

Generally speaking, small-cap growth stocks probably aren't the first place you'd look to invest in during a particularly turbulent market. Underscoring this point, small caps were hit far harder than their mid- and large-cap peers during the height of the COVID-19-induced sell-off in March. Ho...